Haematopoetic stem/progenitor cell therapy - Nohla Therapeutics

Drug Profile

Haematopoetic stem/progenitor cell therapy - Nohla Therapeutics

Alternative Names: Ex vivo expanded universal donor cellular therapies - Nohla Therapeutics; Ex vivo-expanded cord blood progenitor cells - Nohla Therapeutics; Haematopoetic progenitor cell therapy - Nohla Therapeutics; NLA 101; Notch-mediated ex vivo expanded cord blood HSPC - Nohla Therapeutics

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Fred Hutchinson Cancer Research Center; Nohla Therapeutics
  • Class Antibacterials; Antineoplastics; Radioprotectives; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies
  • Preclinical Acute radiation syndrome; Graft-versus-host disease; Neutropenia; Sepsis

Most Recent Events

  • 04 Oct 2017 Nohla Therapeutics plans the phase II LAUNCH trial for Acute myeloid leukaemia (NCT03301597)
  • 28 Mar 2017 Nohla Therapeutics signs a manufacturing and supply agreement with University of California, Davis for development and commercialisation of haematopoetic stem/progenitor cell therapy
  • 10 Jan 2017 Preclinical trials in Graft-versus-host disease (Prevention) in USA (unspecified route) (Nohla Therapeutics pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top